Ionis Pharmaceuticals, Inc. (IONS) Shares Sold by Profund Advisors LLC

Profund Advisors LLC decreased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 4.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,274 shares of the company’s stock after selling 2,156 shares during the period. Profund Advisors LLC’s holdings in Ionis Pharmaceuticals were worth $2,405,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. Teacher Retirement System of Texas increased its holdings in shares of Ionis Pharmaceuticals by 0.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 9,673 shares of the company’s stock worth $492,000 after buying an additional 43 shares during the last quarter. Public Employees Retirement Association of Colorado increased its holdings in shares of Ionis Pharmaceuticals by 0.3% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock worth $1,241,000 after buying an additional 65 shares during the last quarter. Utah Retirement Systems increased its holdings in shares of Ionis Pharmaceuticals by 0.5% in the 1st quarter. Utah Retirement Systems now owns 22,000 shares of the company’s stock worth $884,000 after buying an additional 100 shares during the last quarter. World Asset Management Inc increased its holdings in shares of Ionis Pharmaceuticals by 3.4% in the 2nd quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock worth $286,000 after buying an additional 187 shares during the last quarter. Finally, Prudential Financial Inc. increased its holdings in shares of Ionis Pharmaceuticals by 4.9% in the 2nd quarter. Prudential Financial Inc. now owns 8,641 shares of the company’s stock worth $440,000 after buying an additional 400 shares during the last quarter. 89.33% of the stock is currently owned by hedge funds and other institutional investors.

In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $52.45, for a total transaction of $865,425.00. Following the transaction, the chairman now owns 53,014 shares in the company, valued at $2,780,584.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Patrick R. O’neil sold 1,000 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total transaction of $55,000.00. Following the transaction, the senior vice president now owns 10,633 shares in the company, valued at approximately $584,815. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,309 shares of company stock worth $2,997,692. 1.86% of the stock is owned by insiders.

A number of equities analysts have recently commented on IONS shares. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Monday, July 31st. Jefferies Group LLC reissued an “underperform” rating and issued a $18.00 price target (up previously from $17.00) on shares of Ionis Pharmaceuticals in a report on Thursday, August 10th. BMO Capital Markets reissued a “buy” rating and issued a $59.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, June 2nd. Sanford C. Bernstein started coverage on shares of Ionis Pharmaceuticals in a report on Thursday, July 27th. They issued a “market perform” rating and a $57.00 price target on the stock. Finally, Barclays PLC started coverage on shares of Ionis Pharmaceuticals in a report on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price target on the stock. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $49.31.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/17/ionis-pharmaceuticals-inc-ions-shares-sold-by-profund-advisors-llc.html.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded up 1.47% during trading on Friday, hitting $59.23. 1,501,356 shares of the company traded hands. The stock has a market capitalization of $7.37 billion, a PE ratio of 284.76 and a beta of 3.13. The company’s 50 day moving average is $51.34 and its 200-day moving average is $48.10. Ionis Pharmaceuticals, Inc. has a 52 week low of $24.58 and a 52 week high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). The business had revenue of $104.15 million for the quarter, compared to analysts’ expectations of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. Ionis Pharmaceuticals’s revenue for the quarter was up 170.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.47) EPS. Analysts predict that Ionis Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply